Editor-in-Chief

Sagar Lonial, MD, FACP

Editor-in-Chief

Sagar Lonial, MD, FACP, is Chair and Professor in the Department of Hematology and Medical Oncology, the Anne and Bernard Gray Family Chair in Cancer, and Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine in Atlanta, Georgia.

Dr. Lonial, who has authored or coauthored more than 200 peer-reviewed publications, is “internationally recognized as a leading authority in multiple myeloma treatment and research,” according to his biography from the Winship Cancer Institute.

He is a member of the Society of Hematologic Oncology (SOHO) Board of Directors and Chair of the SOHO Education Committee. Dr. Lonial is also involved with numerous other professional organizations.

Articles by Sagar Lonial, MD, FACP

Sagar Lonial, MD, FACPPrint | January 4, 2024
As we close 2023, it feels like we are all back, at full speed ahead, doing the work that draws us together and to our field.
Read More
Sagar Lonial, MD, FACPMyeloma | December 15, 2023
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH, the PERSEUS trial, and treating smoldering MM.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel compares clinical trial and real-world data for CAR-Ts.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discusses which patients may not be suitable for CAR T-cell therapy.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
The panel discussed how CAR-T impacts myeloma standard of care.
Sagar Lonial, MD, FACPVideo Insights | October 15, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Sagar Lonial, MD, FACPViewpoints | February 8, 2024
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Sagar Lonial, MD, FACPMeeting News | June 9, 2023
Dr. Lonial shares his top highlights in multiple myeloma from the EHA and ASCO meetings.
Sagar Lonial, MD, FACPViewpoints | May 15, 2023
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
Thomas Martin, MDVideo Insights | May 15, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 25, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 3, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | May 5, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | May 3, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | May 4, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.